From parent advocate to nonprofit chief science officer, to biotherapeutic company cofounder — A personal journey through drug development for Angelman syndrome
On May 29, 2020, Allyson Berent will discuss the journey that led her to becoming chief science officer of the largest research funding foundation for Angelman syndrome in the world (Foundation for Angelman Syndrome Therapeutics [FAST]), and the cofounder and chief operating officer of GeneTx Biotherapeutics — a biotech company solely focused on developing an antisense oligonucleotide for the treatment of Angelman syndrome — after her daughter was diagnosed with Angelman syndrome at 5.5 months old.
Join the SFARI science team and leaders in the autism research community for an informal evening of food, drink, conversation and mingling on 14 November 2016 in San Diego.
Associate Professor of Neurology, Harvard Medical School
On 2 November 2016, Beth Stevens discussed recent work that implicates brain immune cells, called microglia, in sculpting of synaptic connections during development and their relevance to autism, schizophrenia and other brain disorders.
Professor in Neurology, Harvard Medical School
On 5 October 2016, Mustafa Sahin presented an update on translational research in Tuberous Sclerosis Complex.
On 7 September 2016, Ruth O'Hara discussed the field’s current understanding of sleep in autism spectrum disorder.
Bullard Professor of Neurology, Harvard Medical School
On 27 April 2016, Christopher Walsh reviewed recent work on ‘somatic mutations’ — de novo mutations that are present in some brain cells but not in all cells of the body — in several neurological conditions associated with intellectual disability and seizures.
On 30 March 2016, Catherine Monk described her lab’s fetal origins of adult disease studies that focus on women in the perinatal period and fetal and infant neurobehavioral development, including direct studies of the fetus, newborn brain imaging and placental methylation.